Crossmark

Comparing Intravenous Racemic Ketamine and Intranasal Esketamine for Treatment-Resistant Depression: A Clinical Dilemma

Published Online: 2025-07-30

Published Print: 2025

Authors

Singh, Balwinder https://orcid.org/0000-0001-7062-8192
Vande Voort, Jennifer L.

Kung, Simon
License Information

Text and Data Mining valid from 2025-01-01

Version of Record valid from 2025-01-01
More Information

Chapter History

First Online: 30 July 2025

Conflict of Interest

: Dr. Singh has received research grant support from Mayo Clinic, the National Network of Depression Centers Momentum grant, and Breakthrough Discoveries for thriving with bipolar disorder (BD2). He is a KL2 Mentored Career Development Program scholar, supported by CTSA grant KL2TR002379 from the National Center for Advancing Translational Science (NCATS). Dr. Singh has received honoraria (to Mayo Clinic) from Elsevier for editing a Clinical Overview on Treatment-Resistant Depression. Dr. Vande Voort has received grant-in-kind support from Assurex Health (unrelated to this study). Dr. Kung received payment for a recorded CME presentation about transcranial magnetic stimulation by Psychopharmacology Institute. Funding sources had no influence on the work reported.

Document is current